Loading clinical trials...
Loading clinical trials...
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Revolution Medicines, Inc.
NCT07446322 · Ras-mutated Metastatic Colorectal Cancer, mCRC, and more
NCT02600949 · Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, and more
NCT06921928 · Gastric Cancer, Gastroesophageal Junction Cancer, and more
NCT05919264 · Cancer, Colorectal Cancer, and more
NCT06423326 · Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, and more
City of Hope
Duarte, California
UC IRVINE Health
Orange, California
UC Davis Comprehensive Cancer Center
Sacramento, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions